W.A. Long

457 total citations
6 papers, 21 citations indexed

About

W.A. Long is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, W.A. Long has authored 6 papers receiving a total of 21 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hepatology, 3 papers in Epidemiology and 2 papers in Rheumatology. Recurrent topics in W.A. Long's work include Hepatitis C virus research (5 papers), Hepatitis B Virus Studies (2 papers) and Systemic Lupus Erythematosus Research (2 papers). W.A. Long is often cited by papers focused on Hepatitis C virus research (5 papers), Hepatitis B Virus Studies (2 papers) and Systemic Lupus Erythematosus Research (2 papers). W.A. Long collaborates with scholars based in United States, Netherlands and Poland. W.A. Long's co-authors include Zobair M. Younossi, E. Läwitz, S. Gordon, R. Balabanska, К. Tchernev, J. McHutchison, M. Shiffman, Rakesh Mehra, Iskren Kotzev and Reem Ghalib and has published in prestigious journals such as Journal of Hepatology.

In The Last Decade

W.A. Long

5 papers receiving 21 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
W.A. Long United States	3	19	18	4	3	2	6	21
Will Rowe United Kingdom	2	14 0.7×	15 0.8×	5 1.3×	2 0.7×		2	19
Hector Velásquez Philippines	2	12 0.6×	14 0.8×	4 1.0×	3 1.0×		2	19
Bebi Yassin-Rajkumar Canada	3	14 0.7×	16 0.9×	7 1.8×	2 0.7×		4	18
Hailemichael Desalegn Mekonnen Ethiopia	3	14 0.7×	15 0.8×	2 0.5×	2 0.7×		5	19
Abel Murillo United States	2	22 1.2×	19 1.1×	7 1.8×	1 0.3×		2	24
Bastian Neesgaard Denmark	3	11 0.6×	8 0.4×	3 0.8×	2 0.7×		3	17
Markus Gess United Kingdom	3	13 0.7×	17 0.9×	8 2.0×	1 0.3×		4	25
Saleh Muhammad Channa Israel	2	25 1.3×	24 1.3×	2 0.5×	1 0.3×	1 0.5×	2	28
Yakup Demir Türkiye	3	11 0.6×	12 0.7×	4 1.0×			9	15
Krestina Brigida Uzbekistan	3	19 1.0×	20 1.1×	2 0.5×	1 0.3×		5	26

Countries citing papers authored by W.A. Long

Since Specialization

Citations

This map shows the geographic impact of W.A. Long's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W.A. Long with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W.A. Long more than expected).

Fields of papers citing papers by W.A. Long

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W.A. Long. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W.A. Long. The network helps show where W.A. Long may publish in the future.

Co-authorship network of co-authors of W.A. Long

This figure shows the co-authorship network connecting the top 25 collaborators of W.A. Long. A scholar is included among the top collaborators of W.A. Long based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W.A. Long. W.A. Long is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Kurtoğlu, Selim, et al.. (2016). Safety and Tolerability of Recurrent Hepatitis C Treatment in Post Liver and Liver/Kidney Transplant Patients Treated with Ledipasvir/Sofosbuvir with and without Ribavirin or Sofosbuvir with Ribavirin: Single Center Experience. Journal of Hepatology. 64(2). S788–S789.

2.

Long, W.A., Zobair M. Younossi, E. Läwitz, et al.. (2011). 446 TIMING AND FREQUENCY OF DEPRESSION DURING HCV-TREATMENT WITH CONTROLLED-RELEASE-IFNA2B (CR2B) VS. PEGYLATED-IFNA2B (PEG2B): RESULTS FROM SELECT-2, A RANDOMIZED-OPEN-LABEL-72-WEEK-COMPARISON IN 116 TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 HCV. Journal of Hepatology. 54. S181–S182. 2 indexed citations

3.

Läwitz, E., et al.. (2011). 444 SVR FOR CONTROLLED-RELEASE INTERFERON ALPHA-2B (CR2B) +RIBAVIRIN COMPARED TO PEGYLATED INTERFERON ALPHA-2B (PEG2B) +RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 (G1) HEPATITIS C: FINAL RESULTS FROM SELECT-2. Journal of Hepatology. 54. S180–S181. 4 indexed citations

4.

Long, W.A., К. Tchernev, Iskren Kotzev, et al.. (2010). 2010 Q2WEEK CONTROLLED-RELEASE-INTERFERON-ALPHA2B + RIBAVRIN REDUCES FLU-LIKE SYMPTOMS >50% AND PROVIDES EQUIVALENT EFFICACY IN COMPARISON TO WEEKLY PEGYLATED-INTERFERON-ALPHA2B + RIBAVIRIN IN TREATMENT-NAIVE-GENOTYPE-1-CHRONIC-HEPATITIS-C: RESULTS FROM EMPOWER, A RANDOMIZED-OPEN-LABEL-12-WEEK-COMPARISON IN 133 PATIENTS. Journal of Hepatology. 52. S467–S467. 7 indexed citations

5.

Kotzev, Iskren, et al.. (2010). 58 RANDOMIZED, OPEN-LABEL, 12-WEEK COMPARISON OF CONTROLLED-RELEASE INTERFERON ALPHA2B +RIBAVRIN VS. PEGYLATED-INTERFERON ALPHA2B +RIBAVRIN IN TREATMENT-NAIVE GENOTYPE1 HEPATITIS C: 4 WEEK RESULTS FROM 480STUDY (PANEL A). Journal of Hepatology. 52. S27–S27. 2 indexed citations

6.

Läwitz, E., Zobair M. Younossi, M. Shiffman, et al.. (2009). 628 RANDOMIZED TRIAL COMPARING SYSTEMIC AND LOCAL REACTIONS TO CONTROLLED-RELEASE INTERFERON ALPHA2B AND PEGYLATED-INTERFERON ALPHA2B IN HEPATITIS C PATIENTS WHO FAILED PRIOR TREATMENT. Journal of Hepatology. 50. S231–S231. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact